Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
2024年8月15日 - 6:00AM
Edgar (US Regulatory)
|
UNITED
STATES |
OMB
APPROVAL |
|
SECURITIES
AND EXCHANGE COMMISSION |
OMB
Number: 3235-0058 |
|
Washington,
D.C. 20549 |
Expires:
April 30, 2025 |
|
|
Estimated
average burden |
|
FORM
12b-25 |
hours
per response ............. 2.50 |
|
|
|
|
|
SEC
FILE NUMBER |
|
NOTIFICATION
OF LATE FILING |
|
|
|
CUSIP
NUMBER |
|
|
|
(Check
one): |
☐
Form 10-K |
☐
Form 20-F |
☐
Form 11-K |
|
|
☒
Form 10-Q |
☐
Form 10-D |
☐
Form N-CEN |
☐
Form N-CSR |
|
For
Period Ended: June 30, 2024 |
|
|
|
☐
Transition Report on Form 10-K |
|
☐
Transition Report on Form 20-F |
|
☐
Transition Report on Form 11-K |
|
☐
Transition Report on Form 10-Q |
|
|
|
For
the Transition Period Ended: __________________________________________ |
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this Form shall be construed to imply that the Commission has verified any information
contained herein. |
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
Arch Therapeutics, Inc.
Full Name of Registrant
Almah,
Inc.
Former
Name if Applicable
235 Walnut Street, Suite 6
Address
of Principal Executive Office (Street and Number)
Framingham,
Massachusetts 01702
City,
State and Zip Code
SEC 1344 (06-19) |
Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form
displays a currently valid OMB control number. |
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
|
(a) |
The
reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense; |
☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report
or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the
fifth calendar day following the prescribed due date; and |
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
Arch
Therapeutics, Inc. (the “Registrant”) has been delayed in filing its Quarterly Report on Form 10-Q (the “Quarterly
Report”) for the nine months ended June 30, 2024, due to a delay in the compilation, dissemination and review of the information
required to be presented by the Registrant in the Quarterly Report, which has imposed time constraints that have rendered timely filing
of the Form 10-Q impracticable without unreasonable effort or expense. The Registrant expects to file the Quarterly Report on or before
August 19, 2024.
PART
IV — OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification |
Terrence W. Norchi |
|
(617) |
|
431-2313 |
(Name) |
|
(Area
Code) |
|
(Telephone
Number) |
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If answer is no, identify report(s). ☒ Yes ☐ No |
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof ? |
|
☐
Yes ☒ No |
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made. |
Arch Therapeutics, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date |
August 14, 2024 |
|
By: |
/s/
Terrence W. Norchi |
INSTRUCTION:
The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of
the person signing the Form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by
an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of
the registrant shall be filed with the Form.
ATTENTION
Intentional
misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001). |
GENERAL INSTRUCTIONS
1. | This Form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange
Act of 1934. |
| |
2. | One signed original and four conformed copies of this Form and amendments thereto must be completed and filed with the Securities
and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the
General Rules and Regulations under the Act. The information contained in or filed with the Form will be made a matter of public record
in the Commission files. |
| |
3. | A manually signed copy of the Form and amendments thereto shall be filed with each national securities exchange on which any class
of securities of the registrant is registered. |
| |
4. | Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that
has been correctly furnished. The Form shall be clearly identified as an amended notification. |
| |
5. | Electronic filers. This form shall not be used by electronic filers unable to timely file a report solely due to electronic difficulties.
Filers unable to submit a report within the time period prescribed due to difficulties in electronic filing should comply with either
Rule 201 or Rule 202 of Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment in filing date pursuant
to Rule 13(b) of Regulation S-T (§232.13(b) of this Chapter). |
| |
6. | Interactive data submissions. This Form shall not be used by electronic filers with respect to the submission or posting of
an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the
time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201
and §232.202 of this chapter). |
Arch Therapeutics (QB) (USOTC:ARTHD)
過去 株価チャート
から 7 2024 まで 8 2024
Arch Therapeutics (QB) (USOTC:ARTHD)
過去 株価チャート
から 8 2023 まで 8 2024